Portal hypertension

Current Opinion in Gastroenterology

Volumn 14, Issue 3, 1998, Pages 256-264

  Garcia Tsao, Guadalupe ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ISOSORBIDE 5 NITRATE; NORFLOXACIN; SOMATOSTATIN; TERLIPRESSIN; TIMOLOL;

BACTERIAL PERITONITIS; BRAIN DISEASE; CHRONIC LIVER DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; ENDOSCOPIC SCLEROTHERAPY; ESOPHAGUS VARICES; ESOPHAGUS VARICES BLEEDING; HUMAN; LIVER CIRRHOSIS; LIVER FAILURE; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PORTOSYSTEMIC ANASTOMOSIS; REVIEW; SIDE EFFECT; SURVIVAL;

EID: 0031943012     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-199805000-00012     Document Type: Review

References (64)

1. Lee FY, Wang SS, Tsai YT, Lin HJ, Chu CJ, Wu SL, Tai CC, Lee SD: Aminoguanidine corrects hyperdynamic circulation without ameliorating portal hypertension and portal hypertensive gastropathy in anesthetized portal hypertensive rats. J Hepatol 1997, 26:687-693.
2. Lopez-Talavera JC, Levitzki A, Martinez M, Gazit A, Esteban R, Guardia J: Tyrosine kinase inhibition ameliorates the hyperdynamic state and decreases nitric oxide production in cirrhotic rats with portal hypertension and ascites. J Clin Invest 1997, 100:664-670.
3. Battista S, Bar F, Mengozzi G, Zanon E, Grosso M, Molino G: Hyperdynamic circulation in patients with cirrhosis: direct measurement of nitric oxide levels in hepatic and portal veins. J Hepatol 1997, 26:75-80.
4. Atucha NM, Shah V, Garcia-Cardena G, Sessa WE, Groszmann RJ: Role of endothelium in the abnormal response of mesenteric vessels in rats with portal hypertension and liver cirrhosis. Gastroenterology 1996, 111:1627-1632.
5. Gadano AC, Sogni P, Yang S, Cailmail S, Moreau R, Nepveux P, Couturier D, Lebrec D: Endothelial calcium-calmodulin dependent nitric oxide synthase in the in vitro vascular hyporeactivity of portal hypertensive rats. J Hepatol 1997, 26:678-686.
6. Morales-Ruiz M, Jimenez W, Perez-Sala D, Ros J, Leivas A, Lamas S, Rivera F, Arroyo V: Increased nitric oxide synthase expression in arterial vessels of cirrhotic rats with ascites. Hepatology 1996, 24:1481-1486. This study suggests that induction of both constitutive (eNOS) and inducible (iNOS) nitric oxide synthase is involved in the increased nitric oxide production responsible for vasodilatation in cirrhosis.
7. Luca A, Garcia-Pagan JC, Bosch J, Feu F, Caballeria J, Groszmann RJ, Rodes J: Effects of ethanol consumption on hepatic hemodynamics in patients with alcoholic cirrhosis. Gastroenterology 1997, 112:1284-1289.
8. Garcia-Pagan JC, Santos C, Barbera JA, Luca A, Roca J, Rodriguez Roisin R, Bosch J, Rodes J: Physical exercise increases portal pressure in patients with cirrhosis and portal hypertension. Gastroenterology 1996, 111:1300-1306.
9. Kravetz D, Romero G, Argonz J, Guevara M, Suarez A, Abecasis R, Bildozola M, Valero J, Terg R: Total volume paracentesis decreases variceal pressure, size and variceal wall tension in cirrhotic patients. Hepatology 1997, 25:59-62. Study that demonstrates a decrease in variceal pressure and size after total paracentesis, suggesting a role for paracentesis in the management of patients with variceal hemorrhage.
10. Iwao T, Toyonaga A, Oho K, Sakai T, Tayama C, Masumoto H, Sato M, Nakahara K, Tanikawa K: Portal-hypertensive gastropathy develops less in patients with cirrhosis and fundal varices. J Hepatol 1997, 26:1235-1241.
11. Merkel C, Sacerdoti D, Bolognesi M, Enzo E, Marin R, Bombonato G, Angeli P, Gatta A: Hemodynamic evaluation of the addition of isosorbide-5-mononitrate to nadolol in cirrhotic patients with insufficient response to β-blocker alone. Hepatology 1997, 26:34-39.
12. Escorsell A, Ferayorni L, Bosch J, Garcia-Pagan JC, Garcia-Tsao G, Grace ND, Rodes J, Groszmann RJ: The portal pressure response to B-blockade is greater in cirrhotic patients without varices than in those with varices. Gastroenterology 1997, 112:2012-2016. This hemodynamic study demonstrates that portal pressure reduction due to beta-blockers is greater in cirrhotic patients without varices, suggesting that pharmacotherapy may be more effective at early stages, prior to the development of varices.
13. Grace ND: Diagnosis and treatment of gastrointestinal bleeding secondary to portal hypertension. Am J Gastroenterol 1997, 92:1081-1091. Guidelines for the therapy and prevention of variceal hemorrhage based on randomized, clinical trials.
14. Hartigan PM, Gebhard RL, Gregory PB: Sclerotherapy for actively bleeding esophageal varices in male alcoholics with cirrhosis. Veterans Affairs Cooperative Variceal Sclerotherapy Group. Gastrointest Endoscopy 1997, 46:1-7.
15. Lo GH, Lai KH, Cheng JS, Lin CK, Huang JS, Hsu PI, Chiang HT: Emergency banding ligation versus Sclerotherapy for the control of active bleeding from esophageal varices. Hepatology 1997, 25:1101-1104.
16. Feu F, Ruiz del Arbol L, Banares R, Planas R, Bosch J: Double-blind randomized controlled trial comparing terlipressin and somatostatin for acute variceal hemorrhage. Variceal Bleeding Study Group. Gastroenterology 1996, 111:1291-1299.
17. Bernard B, Lebrec D, Mathurin P, Opolon P, Poynard T: Propranolol and Sclerotherapy in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. J Hepatol 1997, 26:312-324.
18. Jenkins SA, Baxter JN, Critchley M, Kingsnorth AN, Makin CA, Ellenbogen S, Grime JS, Love JG, Sutton R: Randomised trial of octreotide for long term management of cirrhosis and variceal hemorrhage. BMJ 1997, 315:1338-1341.
19. Sarin SK, Govil A, Jain AK, Guptan RC, Issar S, K., Jain M, Murthy NS: Prospective randomized trial of endoscopic sclerotherapy versus variceal band ligation for esophageal varices: influence on gastropathy, gastric varices and variceal recurrence. J Hepatol 1997, 26:826-832.
20. Avgerinos A, Armonis A, Manolakopoulos S, Poulianos G, Rekoumis G, Sgourou A, Gouma P, Raptis S: Endoscopic sclerotherapy versus variceal ligation in the long-term management of patients with cirrhosis after variceal bleeding. A prospective randomized study. J Hepatol 1997, 26:1034-1041.
21. Baroncini D, Milandri GL, Borioni D, Piemontese A, Cennamo V, Billi P, Dal Monte PP, D'Imperio N: A prospective randomized trial of sclerotherapy versus ligation in the elective treatment of bleeding esophageal varices. Endoscopy 1997, 29:235-240.
22. Laine L, Cook D: Endoscopic ligation compared with sclerotherapy for treatment of esophageal variceal bleeding. A meta-analysis. Ann Int Med 1995, 123:280-287.
23. Leung VKS, Sung JJY, Ahuja AT, Tumala IE, Lee YT, Lau JYW, Chung SCS: Large paraesophageal varices on endosonography predict recurrence of esophageal varices and rebleeding. Gastroenterology 1997, 112:1811-1816.
24. Saeed ZA, Stiegmann GV, Ramirez FC, Reveille RM, Goff JS, Hepps KS, Cole RA: Endoscopic variceal ligation is superior to combined ligation and sclerotherapy for esophageal varices: a multicenter prospective randomized trial. Hepatology 1997, 25:71-74.
25. Bhargava DK, Pokharna R: Endoscopic variceal ligation versus endoscopic variceal ligation and endoscopic sclerotherapy: a prospective randomized study. Am J Gastroenterol 1997, 92:950-953.
26. Rossle M, Deibert P, Haag K, Ochs A, Olschewski M, Siegerstetter V, Hauenstein KH, Geiger R, Stiepak C, Keller W, Blum HE: Randomised trial of transjugular-intrahepatic-portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding. Lancet 1997, 349:1043-1049.
27. Cello JP, Ring EJ, Olcott EW, Koch J, Gordon R, Sandhu J, Morgan DR, Ostroff JW, Rockey DC, Bacchetti P, LaBerge J, Lake JR, Somberg K, Doherty C, Davila M, McQuaid K, Wall SD: Endoscopic sclerotherapy compared with percutaneous transjugular intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal hemorrhage. Ann Int Med 1998, 126:858-865.
28. Sanyal AJ, Freedman AM, Luketic VA, Purdum III PP, Shiffman ML, Cole PE, Tisnado J, Simmons S: Transjugular intrahepatic portosystemic shunts compared with endoscopic sclerotherapy for the prevention of recurrent variceal hemorrhage. A randomized, controlled trial. Ann Int Med 1997, 126:849-857.
29. Sanyal AJ, Freedman AM, Luketic VA, Purdum III PP, Shiffman ML, DeMeo J, Cole PE, Tisnado J: The natural history of portal hypertension after transjugular intrahepatic portosystemic shunts. Gastroenterology 1998, 112:889-898. A hemodynamic study that shows a high rate of stent dysfunction, mostly secondary to stenosis, in the first 2 years post-TIPS.
30. D'Amico G, Pagliaro L, Bosch J: The treatment of portal hypertension: a meta-analytic review. Hepatology 1995, 22:332-354.
31. Teran JC, Imperiale TF, Mullen KD, Tavill AS, McCullough AJ: Primary prophylaxis of variceal bleeding in cirrhosis: A cost-effectiveness analysis. Gastroenterology 1997, 112:473-482.
32. Angelico M, Carli L, Piat C, Gentile S, Rinaldi V, Bologna E, Capocaccia L: Isosorbide-5-mononitrate versus propranolol in the prevention of first bleeding in cirrhosis. Gastroenterology 1993, 104:1460-1465.
33. Angelico M, Carli L, Piat C, Gentile S, Capocaccia L: Effects of isosorbide-5-mononitrate compared with propranolol on first bleeding and long-term survival in cirrhosis. Gastroenterology 1997, 113:1632-1639. Study on the long-term efficiency of propranolol versus nitrates for first variceal hemorrhage, showing a greater mortality in patients older than 50 years treated with isosorbide-5-mononitrate.
34. Groszmann RJ: β-Adrenergic blockers and nitrovasodilators for the treatment of portal hypertension: the good, the bad, the ugly. Gastroenterology 1998, 113:1794-1797. An important and rational analysis of pharmacotherapy in the prevention of first variceal hemorrhage.
35. Merkel C, Marin R, Enzo E, Donada C, Cavallarin G, Torboli P, Amodio P, Sebastianelli G, Sacerdoti D, Felder M, Mazzaro C, Beltrame P, Gatta A, and Gruppo Triveneto per L'lpertensione portale: Randomised trial of nadolol alone or with isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Lancet 1997, 348:1677-1681.
36. Lay CS, Tsai YT, Teg CY, Shyu WS, Guo W, S., Wu KL, Lo KJ: Endoscopic variceal ligation in prophylaxis of first variceal bleeding in cirrhotic patients with high-risk esophageal varices. Hepatology 1997, 25:1346-1350.
37. Wong F, Sniderman K, Liu P, Blendis L: The mechanism of the initial natriuresis after transjugular intrahepatic portosystemic shunt Gastroenterology 1997, 112:899-907.
38. Gines P, Fernandez-Esparrach G, Arroyo V, Rodes J: Pathogenesis of ascites in cirrhosis. Sem Liv Dis 1997, 17:175-189.
39. Gines A, Fernandez-Esparrach G, Monescillo A, Vila C, Domenech E, Abecasis R, Angeli P, Ruiz-del-Arbol L, Planas R, Sola R, Gines P, Terg R, Inglada L, Vaque P Salerno F, Vargas V, Clemente G, Quer JC, Jimenez W, Arroyo V, Rodes J: Randomized trial comparing albumin, dextran-70 and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996, 111:1002-1010.
40. Ruiz del Arbol L, Monescillo A, Jimenez W, Garcia-Plaza A, Arroyo V, Rodes J: Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology 1997, 113:579-586. An important study that determines that post-paracentesis circulatory dysfunction, a syndrome that carries a bad prognosis, is due to worsening vasodilatation and hypovolemia.
41. Fernandez-Esparrach G, Guevara M, Sort P, Pardo A, Jimenez W, Gines P, Planas R, Lebrec D, Geuvel A, Elewaut A, Adler M, Arroyo V: Diuretic requirements after therapeutic paracentesis in non-azotemic patients with cirrhosis. A randomized double-blind trial of spironolactone versus placebo. J Hepatol 1997, 26:614-620.
42. Strauss RM, Boyer TD: Hepatic hydrothorax. Sem Liv Dis 1997, 17:227-232. A needed review of an infrequent complication of cirrhosis.
43. Gordon FD, Anastopoulos HT, Crenshaw W, Gilchrist B, McEniff N, Falchuk KR, LoCicero III J, Lewis D, Jenkins RL, Trey C: The successful treatment of symptomatic, refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt. Hepatology 1997, 25:1366-1369.
44. Bataller R, Gines P, Guevara M, Arroyo V: Hepatorenal syndrome. Sem Liv Dis 1997, 17:233-247.
45. Salo J, Gines A, Quer JC, Fernandez-Esparrach G, Guevara M, Gines P, Bataller R, Planas R, Jimenez W, Arroyo V, Rodes J: Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome. J Hepatol 1996, 25:916-923.
46. Guarner C, Soriano G: Spontaneous bacterial peritonitis. Sem Liv Dis 1997, 17:203-217.
47. Guarner C, Runyon BA, Young S, Heck M, Sheikh MY: Intestinal bacterial overgrowth and bacterial translocation in cirrhotic rats with ascites. J Hepatol 1997, 26:1372-1378.
48. Morales-Ruiz M, Jimenez W, Ros J, Sole M, Leivas A, Bosch-Marce M, Rivera F, Arroyo V, Rodes J: Nitric oxide production by peritoneal macrophages of cirrhotic rats: a host response against bacterial peritonitis. Gastroenterology 1997, 112:2056-2064.
49. Bories PN, Campillo B, Azaou L, Scherman E: Long-lasting NO overproduction in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 1997, 25:1328-1333.
50. Tito L, Rimola A, Gines P, Llach J, Arroyo V, Rodes J: Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. Hepatology 1988, 8:27-31.
51. Younossi ZM, McHutchison JG, Ganiats TG: An economic analysis of norftoxacin prophylaxis against spontaneous bacterial peritonitis. J Hepatol 1997, 27:295-298.
52. Novella M, Sola R, Soriano G, Andreu M, Gana J, Ortiz J, Coll S, Sabat M, Vila MC, Guarner C, Vilardell F: Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin. Hepatology 1997, 25:532-536. First published controlled trial of primary prophylaxis of spontaneous bacterial peritonitis, which also has the longest treatment period. Demonstrates the emergence of antibiotic-resistant bacteria with long-term prophylaxis.
53. Llovet JM, Rodriguez-Iglesias P, Moitinho E, Planas R, Bataller R, Navasa M, Menacho M, Pardo A, Castells A, Cabre E, Arroyo V, Gassull MA, Rodes J: Spontaneous bacterial peritonitis in patients with cirrhosis undergoing selective intestinal decontamination. A retrospective study of 229 spontaneous bacterial peritonitis episodes. J Hepatol 1997, 26:88-95.
54. Kril J, Butterworth RF: Diencephalic and cerebellar pathology in alcoholic and nonalcoholic patients with end-stage liver disease. Hepatology 1997, 26:837-841. Interesting anatomopathologic study showing neuropathology, other than astrocytosis, in a significant proportion of cirrhotic patients who had died in hepatic coma.
55. Rao VL, Audet RM, Butterworth RF: Increased neuronal nitric oxide synthase expression in brain following portacaval anastomosis. Brain Research 1997, 765:169-172.
56. MacDonald GA, Frey KA, Agranoff BW, Minoshima S, Koeppe RA, Kuhl DE, Shulkin BL, Lucey MR: Cerebral benzodiazepine receptor binding in vivo in patients with recurrent hepatic encephalopathy. Hepatology 1997, 26:277-282.
57. Krieger S, Jauss M, Janse O, Stiehl A, Sauer P, Geibler M, Theilmann L, Krieger D: MRI findings in chronic hepatic encephalopathy depend on portosystemic shunt: results of a controlled prospective clinical investigation. J Hepatol 1997, 27:121-126.
58. Spahr L, Butterworth RF, Fontaine S, Bui L, Therrien G, Milette PC, Lebrun LH, Zayed J, Leblanc A, Pomier-Layrargues G: Increased blood manganese in cirrhotic patients: relationship to pallidal magnetic resonance signal hyperintensity and neurological symptoms. Hepatology 1996, 24:1116-1120.
59. Hazell AS, Norenberg MD: Manganese decreases glutamate uptake in cultured astrocytes. Neurochemical Research 1997, 22:1443-1447.
60. Steindl PE, Coy DL, Finn B, Zee PC, Blei AT: A low-protein diet ameliorates disrupted diurnal locomotor activity in rats after portacaval anastomosis. Am J Physiol 1996, 271 :G555-G560.
61. Cordoba J, Dupuis J, Gottstein J, Blei AT: Stenosis of a portacaval anastomosis affects circadian locomotor activity in the rat: a multivariable analysis. Am J Physiol 1997, 36:G1218-G1225. This study validates an experimental model of porto-sytemic encephalopathy and its "clinical" manifestation.
62. Kircheis G, Nilius R, Held C, Berndt H, Buchner M, Gortelmeyer R, Hendricks R, Kruger B, Kuklinski B, Meister H, Otto H, Rink C, Rosch W, Stauch S: Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology 1997, 25:1351-1360.
63. Peck-Radosavljevic M, Zacher J, Meng YG, Pidlich J, Lipinski E, Lange F, Steininger R, Muhlbacher F, Gangl A: Is inadequate thrombopoietin production a major cause of thrombocytopenia in cirrhosis of the liver? J Hepatol 1997, 27:127-131.
64. Pursnani KG, Sillin LF, Kaplan DS: Effect of transjugular intrahepatic portosystemic shunt on secondary hypersplenism. Am J Surg 1997, 173:169-173.